Prof Alan Burnett
Key Publications
Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukaemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomised trial.Milligan DW, Wheatley K, Littlewood T, Craig JO, Burnett AK. Blood. Feb 16: 2006 IF 9.782
No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukaemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukaemia, from the UK MRC AML10 and 12 trials. Gale RE, Hills R, Kottaridis PD, Srirangan S, Wheatley K, Burnett AK, Linch DC. Blood. Nov 15; 106(10):3658-65. 2005 IF 9.782
A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukaemia. Kell WJ, Burnett AK, Chopra R, Yin JA, Clark RE, Rohatiner A, Culligan D, Hunter A, Prentice AG, Milligan DW. Blood. Dec 15; 102 (13);4277-83. 2003 IF 9.782
Attempts to improve treatment outcomes in acute myeloid leukaemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Goldstone AH, Burnett AK, Wheatley K, Smith AG, Hutchinson RM, Clark RE; Medical Research Council Adult Leukaemia Working Party. Blood. Sep1;98(5):1302-11. 2001 IF 9.782
Key Projects
Project Name: AML 16 - A Programme of Treatment Development for AML in Older Patients
Funder: Cancer Research UK
Duration: 6 Years
Value: £98,976
Project Name: Evaluation of Forodosine in AML in vitro studies
Funder: Mundipharma Int. Ltd
Duration: 1 Year
Value: £66,584
Project: Wales Experiment Cancer Medicine Centre
Funder: Cancer Research UK
Duration: 5 Years
Value: £1,436,510